05/03/23 Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics, Inc., a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
